CRUK & MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.
Early Oncology, AstraZeneca, Cambridge, UK.
Br J Cancer. 2021 May;124(11):1809-1819. doi: 10.1038/s41416-021-01296-y. Epub 2021 Mar 19.
The radiosensitising effect of the poly(ADP-ribose) polymerase inhibitor olaparib on tumours has been reported. However, its effect on normal tissues in combination with radiation has not been well studied. Herein, we investigated the therapeutic index of olaparib combined with hemithoracic radiation in a urethane-induced mouse lung cancer model.
To assess tolerability, A/J mice were treated with olaparib plus whole thorax radiation (13 Gy), body weight changes were monitored and normal tissue effects were assessed by histology. In anti-tumour (intervention) studies, A/J mice were injected with urethane to induce lung tumours, and were then treated with olaparib alone, left thorax radiation alone or the combination of olaparib plus left thorax radiation at 8 weeks (early intervention) or 18 weeks (late intervention) after urethane injection. Anti-tumour efficacy and normal tissue effects were assessed by visual inspection, magnetic resonance imaging and histology.
Enhanced body weight loss and oesophageal toxicity were observed when olaparib was combined with whole thorax but not hemithorax radiation. In both the early and late intervention studies, olaparib increased the anti-tumour effects of hemithoracic irradiation without increasing lung toxicity.
The addition of olaparib increased the therapeutic index of hemithoracic radiation in a mouse model of lung cancer.
多聚(ADP-核糖)聚合酶抑制剂奥拉帕尼已被报道具有放射增敏作用。然而,其与放射联合用于正常组织的效果尚未得到充分研究。在此,我们在乌头碱诱导的小鼠肺癌模型中研究了奥拉帕尼联合半胸部放疗的治疗指数。
为评估耐受性,A/J 小鼠接受奥拉帕尼联合全胸放疗(13Gy)治疗,监测体重变化,并通过组织学评估正常组织效应。在抗肿瘤(干预)研究中,A/J 小鼠注射乌头碱诱导肺癌,然后在注射乌头碱 8 周(早期干预)或 18 周(晚期干预)后单独使用奥拉帕尼、单独左胸放疗或奥拉帕尼联合左胸放疗治疗。通过肉眼观察、磁共振成像和组织学评估抗肿瘤疗效和正常组织效应。
与单纯半胸部放疗相比,奥拉帕尼联合全胸部放疗时观察到体重明显减轻和食管毒性增加。在早期和晚期干预研究中,奥拉帕尼增加了半胸部照射的抗肿瘤效果,而不增加肺毒性。
在肺癌小鼠模型中,奥拉帕尼增加了半胸部放疗的治疗指数。